These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34097124)

  • 1. The effects of trazodone on human cognition: a systematic review.
    Gonçalo AMG; Vieira-Coelho MA
    Eur J Clin Pharmacol; 2021 Nov; 77(11):1623-1637. PubMed ID: 34097124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers.
    La AL; Walsh CM; Neylan TC; Vossel KA; Yaffe K; Krystal AD; Miller BL; Karageorgiou E
    J Alzheimers Dis; 2019; 67(3):911-921. PubMed ID: 30689583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Trazodone--its multifunctional mechanism of action and clinical use].
    Frecska E
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):477-82. PubMed ID: 21220793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: pharmacology and clinical practice.
    Cuomo A; Ballerini A; Bruni AC; Decina P; Di Sciascio G; Fiorentini A; Scaglione F; Vampini C; Fagiolini A
    Riv Psichiatr; 2019; 54(4):137-149. PubMed ID: 31379379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized-Controlled Trial Targeting Cognition in Early Alzheimer's Disease by Improving Sleep with Trazodone (REST).
    Eyob E; Shaw JS; Bakker A; Munro C; Spira A; Wu M; Rabinowitz JA; Peters M; Wanigatunga S; Zipunnikov V; Thompson R; Burhanullah MH; Leoutsakos JM; Rosenberg P; Greenberg B
    J Alzheimers Dis; 2024; 101(s1):S205-S215. PubMed ID: 39422935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Label Trazodone Prescription: Evidence, Benefits and Risks.
    Bossini L; Coluccia A; Casolaro I; Benbow J; Amodeo G; De Giorgi R; Fagiolini A
    Curr Pharm Des; 2015; 21(23):3343-51. PubMed ID: 26088119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of trazodone use in psychiatric and medical conditions.
    Khouzam HR
    Postgrad Med; 2017 Jan; 129(1):140-148. PubMed ID: 27744763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers.
    Sasada K; Iwamoto K; Kawano N; Kohmura K; Yamamoto M; Aleksic B; Ebe K; Noda Y; Ozaki N
    Hum Psychopharmacol; 2013 May; 28(3):281-6. PubMed ID: 23661283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Trazodone Contramid® in clinical practice: personalizing antidepressant intervention].
    Fagiolini A; Amodeo G; Goracci A; Blardi P
    Riv Psichiatr; 2016; 51(4):123-128. PubMed ID: 27727261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of trazodone-induced delirium.
    Lennkh C; Fischer P; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Sep; 13(5):225-8. PubMed ID: 9817628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trazodone for erectile dysfunction: a systematic review and meta-analysis.
    Fink HA; MacDonald R; Rutks IR; Wilt TJ
    BJU Int; 2003 Sep; 92(4):441-6. PubMed ID: 12930437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
    Sheehan DV; Rozova A; Gossen ER; Gibertini M
    Psychopharmacol Bull; 2009; 42(4):5-22. PubMed ID: 20581790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
    Saletu-Zyhlarz GM; Anderer P; Arnold O; Saletu B
    Neuropsychobiology; 2003; 48(4):194-208. PubMed ID: 14673218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of mental disorders caused or triggered by somatic and neurological diseases with the use of the multimodal antidepressant trazodone].
    Romanov DV; Samsonova MD; Iuzbashian PG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(4. Vyp. 2):81-89. PubMed ID: 37141133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
    Osváth P
    Neuropsychopharmacol Hung; 2013 Sep; 15(3):147-55. PubMed ID: 24108179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.
    Settimo L; Taylor D
    J Psychopharmacol; 2018 Jan; 32(1):96-104. PubMed ID: 29332554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trazodone use and risk of dementia: A population-based cohort study.
    Brauer R; Lau WCY; Hayes JF; Man KKC; Osborn DPJ; Howard R; Kim J; Wong ICK
    PLoS Med; 2019 Feb; 16(2):e1002728. PubMed ID: 30721226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label uses of trazodone: a review.
    Bossini L; Casolaro I; Koukouna D; Cecchini F; Fagiolini A
    Expert Opin Pharmacother; 2012 Aug; 13(12):1707-17. PubMed ID: 22712761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Unfolded Protein Response as a Disease-Modifying Pathway in Dementia.
    Sidhom E; O'Brien JT; Butcher AJ; Smith HL; Mallucci GR; Underwood BR
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.